![]() |
Office of the
|
|
|
|
Office of SciencePolicy |
| NIH/PHS | FDA | OIG | Other |
42
CFR Part 50, Subpart F. Responsibility of Applicants for Promoting Objectivity
in Research for Which PHS Funding Is Sought
"This subpart promotes objectivity in research by establishing standards
to ensure there is no reasonable expectation that the design, conduct, or
reporting of research funded under PHS grants or cooperative agreements will
be biased by any conflicting financial interest of an Investigator."
Frequently Asked Questions Concerning the Department of Health and Human Services' Objectivity in Research Regulations and the National Science Foundation Investigator Financial Disclosure Policy as published in the Federal Register: July 3, 1996 Volume 61, Number 129, p. 34839.
Required Education in the Protection of Human Research Participants. NIH Guidance, June 5, 2000
Financial Conflicts of Interest and Research Objectivity: Issues for Investigators and Institutional Review Boards. NIH Guidance, June 5, 2000.
Terms and Conditions of NIH Grant Awards
FDA Guidance for Institutional Review Boards and Clinical Investigators (9/98) including
FDA Guidance For Industry: Financial Disclosure by Clinical Investigators (October 25, 1999).
FDA Press Release: "FDA Announces Financial Disclosure Rules" (February 2, 1998).
Conference Announcement in the Federal Register
45 CFR Part 46, Subpart A. Basic HHS Policy for Protection of Human Research Subjects.
HHS Debarment Regulations - 45 CFR Part 76
For more information please contact coi@osaspe.dhhs.gov
[Search all ASPE pages. | ASPE Home | HHS HomePage]
Last revised 6/15/00.